微泰医疗-B(02235)持续葡萄糖监测系统海外获批将极大拓宽海外市场覆盖半径

智通财经

Nov 26

智通财经APP讯，微泰医疗-B(02235)发布公告，公司的LinX(AiDEX X的国际品牌名)持续葡萄糖监测系统，近期获得印度的上市批准，适用于成人的连续动态血糖监测。LinX系统凭借其卓越性能与可靠性，不仅成功纳入欧洲多国医疗保障体系，亦在中东、亚太及南美等新兴市场完成多国准入，构筑了多元化、可持续的国际业务支撑体系。

近年来，全球持续葡萄糖监测市场呈现强劲增长态势。印度作为新兴市场的核心代表，具备广阔的市场潜力：根据IDF《2025全球糖尿病地图》数据，印度20-79岁糖尿病患者约8983万人，患病率达9.5%，患病人数高居全球第二位;糖尿病相关死亡数位列全球第一。更为严峻的是，糖尿病前期的患病率也正不断提升，且疾病呈现显着的年轻化趋势，防控体系存在巨大缺口，这为数位化、智能化的糖尿病管理方案创造了迫切且庞大的需求。

公司LinX持续葡萄糖监测系统在印度获批上市，标志着公司成功进入这一极具战略意义的高增长市场。此举将极大拓宽公司的海外市场覆盖半径，为国际业务的规模化扩张与收入增长奠定坚实基础。

未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发展，持续推动相关领域技术与产品创新。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2586254341"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586254341\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586254341?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-26 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586254341","market":"fut","top_or_hot":-1,"title":"微泰医疗-B(02235)持续葡萄糖监测系统海外获批 将极大拓宽海外市场覆盖半径","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02235\">微泰医疗-B</a>(02235)发布公告，公司的LinX(AiDEX X的国际品牌名)持续葡萄糖监测系统，近期获得印度的上市批准，适用于成人的连续动态血糖监测。LinX系统凭借其卓越性能与可靠性，不仅成功纳入欧洲多国医疗保障体系，亦在中东、<a href=\"https://laohu8.com/S/002540\">亚太</a>及南美等新兴市场完成多国准入，构筑了多元化、可持续的国际业务支撑体系。</p><p>近年来，全球持续葡萄糖监测市场呈现强劲增长态势。印度作为新兴市场的核心代表，具备广阔的市场潜力：根据IDF《2025全球糖尿病地图》数据，印度20-79岁糖尿病患者约8983万人，患病率达9.5%，患病人数高居全球第二位;糖尿病相关死亡数位列全球第一。更为严峻的是，糖尿病前期的患病率也正不断提升，且疾病呈现显着的年轻化趋势，防控体系存在巨大缺口，这为数位化、智能化的糖尿病管理方案创造了迫切且庞大的需求。</p><p>公司LinX持续葡萄糖监测系统在印度获批上市，标志着公司成功进入这一极具战略意义的高增长市场。此举将极大拓宽公司的海外市场覆盖半径，为国际业务的规模化扩张与收入增长奠定坚实基础。</p><p>未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发展，持续推动相关领域技术与产品创新。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微泰医疗-B(02235)持续葡萄糖监测系统海外获批 将极大拓宽海外市场覆盖半径</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微泰医疗-B(02235)持续葡萄糖监测系统海外获批 将极大拓宽海外市场覆盖半径\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-26 20:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1374094.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微泰医疗-B(02235)发布公告，公司的LinX(AiDEX X的国际品牌名)持续葡萄糖监测系统，近期获得印度的上市批准，适用于成人的连续动态血糖监测。LinX系统凭借其卓越性能与可靠性，不仅成功纳入欧洲多国医疗保障体系，亦在中东、亚太及南美等新兴市场完成多国准入，构筑了多元化、可持续的国际业务支撑体系。近年来，全球持续葡萄糖监测市场呈现强劲增长态势。印度作为新兴市场的核心代表...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1374094.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1374094.html","article_id":"2586254341","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586254341","pubTimestamp":1764159566,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微泰医疗-B 发布公告，公司的LinX持续葡萄糖监测系统，近期获得印度的上市批准，适用于成人的连续动态血糖监测。近年来，全球持续葡萄糖监测市场呈现强劲增长态势。公司LinX持续葡萄糖监测系统在印度获批上市，标志着公司成功进入这一极具战略意义的高增长市场。此举将极大拓宽公司的海外市场覆盖半径，为国际业务的规模化扩张与收入增长奠定坚实基础。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1100":"医疗保健设备","02235":"微泰医疗-B"},"translate_title":"Weitai Medical-B (02235) continuous glucose monitoring system approved overseas, which will greatly expand overseas market coverage","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02235":1.5},"content_text":"智通财经APP讯，微泰医疗-B(02235)发布公告，公司的LinX(AiDEX X的国际品牌名)持续葡萄糖监测系统，近期获得印度的上市批准，适用于成人的连续动态血糖监测。LinX系统凭借其卓越性能与可靠性，不仅成功纳入欧洲多国医疗保障体系，亦在中东、亚太及南美等新兴市场完成多国准入，构筑了多元化、可持续的国际业务支撑体系。近年来，全球持续葡萄糖监测市场呈现强劲增长态势。印度作为新兴市场的核心代表，具备广阔的市场潜力：根据IDF《2025全球糖尿病地图》数据，印度20-79岁糖尿病患者约8983万人，患病率达9.5%，患病人数高居全球第二位;糖尿病相关死亡数位列全球第一。更为严峻的是，糖尿病前期的患病率也正不断提升，且疾病呈现显着的年轻化趋势，防控体系存在巨大缺口，这为数位化、智能化的糖尿病管理方案创造了迫切且庞大的需求。公司LinX持续葡萄糖监测系统在印度获批上市，标志着公司成功进入这一极具战略意义的高增长市场。此举将极大拓宽公司的海外市场覆盖半径，为国际业务的规模化扩张与收入增长奠定坚实基础。未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发展，持续推动相关领域技术与产品创新。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}